Zim Laboratories (NSE:ZIMLAB) LT-Debt-to-Total-Asset: 0.08 (As of Mar. 2026)

What is Zim Laboratories LT-Debt-to-Total-Asset?

Zim Laboratories NSE:ZIMLAB -2.32% 76 LT-Debt-to-Total-Asset is 0.08 as of Mar. 2026. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 76/100 and a GF Value™ of ₹103.08 (Modestly Overvalued). The stock has 8 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Zim Laboratories's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.08.

Zim Laboratories's long-term debt to total assets ratio declined from Mar. 2025 (0.09) to Mar. 2026 (0.08). It may suggest that Zim Laboratories is progressively becoming less dependent on debt to grow their business.

Zim Laboratories (NSE:ZIMLAB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Zim Laboratories LT-Debt-to-Total-Asset Related Terms

Zim Laboratories LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Zim Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zim Laboratories LT-Debt-to-Total-Asset Chart

Zim Laboratories Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.08

0.09

0.08

Zim Laboratories Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.09	0.00	0.10	0.00	0.08

76GF Score

Zim Laboratories Ltd NSE:ZIMLAB

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Zim Laboratories LT-Debt-to-Total-Asset Calculation

Zim Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )	/	Total Assets (A: Mar. 2026 )
	=	424.203	/	5393.871
	=	0.08

Zim Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	424.203	/	5393.871
	=	0.08

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.08 mean?

Zim Laboratories (NSE:ZIMLAB) has a LT-Debt-to-Total-Asset of 0.08 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Zim Laboratories and its competitors.

Is Zim Laboratories' LT-Debt-to-Total-Asset too high?

Zim Laboratories' current LT-Debt-to-Total-Asset is 0.08. Overall, Zim Laboratories has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Zim Laboratories' LT-Debt-to-Total-Asset compare to ZTS?

Zim Laboratories' LT-Debt-to-Total-Asset of 0.08 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Zim Laboratories and its competitors. Zim Laboratories's current LT-Debt-to-Total-Asset is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Zim Laboratories stock overvalued right now?

Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹103.08, compared to a current price of ₹124.90 — trading 21.2% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.08. Zim Laboratories' overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current LT-Debt-to-Total-Asset is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued. The current stock price of ₹124.90 is trading 21.2% above its estimated GF Value™ of ₹103.08. GuruFocus considers Zim Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:ZIMLAB:

LT-Debt-to-Total-Asset: 0.08
GF Value™: ₹103.08 vs. price of ₹124.90 (21.2% above fair value)
GF Score™: 76/100 with 8 warning signs

No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zim Laboratories Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies BOM:530477 NSE:INFLUX BOM:524731 NSE:AMANTA BOM:524500 BOM:543998 BOM:524075 BOM:540937 BOM:531146 NSE:AHCL XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges 541400:India

Address Nelson Square, Chhindwara Road, Sadoday Gyan, Ground Floor, Opposite NADT, Nagpur, MH, IND, 440 013

Website https://www.zimlab.in

Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.

76GF Score

Get the complete analysis for NSE:ZIMLAB

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹124.90

Price

₹103.08

GF Value

View NSE:ZIMLAB Analysis

See LT-Debt-to-Total-Asset data for all stocks →